GLP-1受体激动剂和DPP-4抑制剂在糖尿病治疗中的研究进展

Research progress on GLP-1 receptor agonis and DPP-4 inhibitor in treatment of diabetes

随着肠促胰素的发现,胰岛α细胞及胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂的研究逐渐成为新的糖尿病研究热点。本文旨在通过分析糖尿病状态下胰岛细胞病理生理变化及比较两类药物在临床应用中的疗效及安全性,为糖尿病患者,尤其是胰岛功能衰竭的患者提供此两类药物的一些应用指导。

Along with incretin was found,the researches on glucagon- likepeptide- 1（ GLP- 1） receptor agonist and dipeptidylpeptidase- 4（ DPP- 4） inhibitor have been coming to be the new hot area of researches on diabetes. The article analyzed the pathophysiologic changes of islet cells under the diabetic state,and compared the therapeutic effect and security of GLP- 1 and DPP- 4,in order to provide the reference for chosing GLP- 1 and DPP- 4,especially for those whose pancreatic islet had nonfunction.